Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Current Leases: 2021-2024

Historic Current Leases for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $2.0 million.

  • Kiniksa Pharmaceuticals International's Current Leases rose 32.74% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 32.74%. This contributed to the annual value of $2.0 million for FY2024, which is 11.54% down from last year.
  • Kiniksa Pharmaceuticals International's Current Leases amounted to $2.0 million in FY2024, which was down 11.54% from $2.3 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Current Leases ranged from a high of $3.4 million in FY2021 and a low of $2.0 million during FY2024.
  • Its 3-year average for Current Leases is $2.5 million, with a median of $2.3 million in 2023.
  • Data for Kiniksa Pharmaceuticals International's Current Leases shows a maximum YoY tumbled of 31.75% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Kiniksa Pharmaceuticals International's Current Leases stood at $3.4 million in 2021, then declined by 2.37% to $3.3 million in 2022, then plummeted by 31.75% to $2.3 million in 2023, then fell by 11.54% to $2.0 million in 2024.